Diese Webseite nutzt Cookies

Diese Webseite nutzt Cookies zur Verbesserung des Erlebnisses unserer Besucher. Indem Sie weiterhin auf dieser Webseite navigieren, erklären Sie sich mit unserer Verwendung von Cookies einverstanden.

Essenzielle Cookies ermöglichen grundlegende Funktionen und sind für die einwandfreie Funktion der Website erforderlich.
Statistik Cookies erfassen Informationen anonym. Diese Informationen helfen uns zu verstehen, wie unsere Besucher unsere Website nutzen.
Marketing-Cookies werden von Drittanbietern oder Publishern verwendet, um personalisierte Werbung anzuzeigen. Sie tun dies, indem sie Besucher über Websites hinweg verfolgen.

Clinical Needs Driving Radiopharmaceutical Research and Scalable Solutions

When: Sunday, June 9th | 6:30pm - 7:30pm
Where: Toronto Convention Center | South Building, 700 Level, Room 701B

Overview

This session will examine the well-established clinical utility of beta-emitting Lu-177 therapies and the potential of alpha-emitting Ac-225 and Auger-emitting
Tb-161, ongoing research to support the development of new radiopharmaceuticals, and how a sustainable supply of isotopes is being established to address the rapidly growing demands for clinicians and researchers.

 

Attendance is free to all attendees of the SNMMI Annual Meeting.
For more information or to register to attend SNMMI click here:

SNMMI.org 

Watch the introduction below and register now to access the full program

Roger
Estafanos

Session Moderator

General Manager, ITM USA

Munir
Ghesani, MD

Expanding the use of theranostics & the clinical management of patients

Chief Medical Officer, UNITED THERANOSTICS

Danielle
Meyrick, PhD, MD

Growing Pipeline to Address Unmet Clinical Needs

Chief Medical Officer, ITM

Mark
Harfensteller, PhD

Scalable Solutions to Meet the Rapidly Growing Needs

Chief Operating Officer, ITM

Roger
Estafanos

Session Moderator

General Manager, ITM USA

Munir
Ghesani, MD

Expanding the use of theranostics & the clinical management of patients

Chief Medical Officer, UNITED THERANOSTICS

Danielle
Meyrick, PhD, MD

Growing Pipeline to Address Unmet Clinical Needs

Chief Medical Officer, ITM

Mark
Harfensteller, PhD

Scalable Solutions to Meet the Rapidly Growing Needs

Chief Operating Officer, ITM

ITM Isotope Technologies Munich SE
Lichtenbergstrasse 1
85748 Garching / Munich, Germany
Email: info(at)itm-radiopharma.com
Phone: +49 89 329 8986 6000
Fax: +49 89 329 8986 6061